Development of orally active inhibitors of protein and cellular fucosylation
Nicole M. Okeley(Seagen (United States)), Peter D. Senter(North Carolina Central University), Weiping Zeng(Seagen (United States)), Tamar E. Boursalian(Seagen (United States)), Brian E. Toki(Seagen (United States)), Django Sussman(Seagen (United States)), Scott C. Jeffrey(Seagen (United States)), Che‐Leung Law(Seagen (United States)), Martha E. Anderson(Seagen (United States)), Lori Westendorf(Seagen (United States)), Stephen C. Alley(Seagen (United States)), Xinqun Zhang(Seagen (United States)), Kim M. Emmerton(Seagen (United States)), Kerry Klussman(Seagen (United States)), Dennis R. Benjamin(Seagen (United States)), Patrick Burke(Seagen (United States))
Cited by 189
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772